A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.
Epistemonikos ID: 91aa7b16c85c320d173ddd1fe7add9e11ef76c30
First added on: Jul 09, 2025